CMBA
TBPH

C.M. Bidwell & Associates’s Theravance Biopharma TBPH Stock Holding History

C.M. Bidwell & Associates’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-255
Closed -$4.77K – 521
2025
Q4 		$4.77K Buy
+255
New +$4.23K ﹤0.01% 332

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

C.M. Bidwell & Associates's TBPH Position: Q1 2026 in Review

C.M. Bidwell & Associates sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 255 shares — an estimated $4.77K sold.

C.M. Bidwell & Associates first reported a position in TBPH in Q4 2025 and held it in 1 quarter. The position peaked at $4.77K in Q4 2025. 174 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • C.M. Bidwell & Associates reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 255 Theravance Biopharma shares in Q1 2026, an estimated $4.77K.
  • C.M. Bidwell & Associates first reported a position in Theravance Biopharma in Q4 2025 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Theravance Biopharma position peaked at $4.77K in Q4 2025.
  • 174 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2026, filed 15 May 2026.